![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Activity of danoprevir plus low-dose ritonavir in combination with peginterferon alfa-2a (40KD) plus ribavirin in previous null responders
|
|
|
Reported by Jules Levin EASL 2011 Berlin Germany March 31-April 3
R. Rouzier1, D. Larrey2, E.J. Gane3, A. Wiercinska-Drapalo4, L. Chang5,
Y. Zhang5, B. Gujral6, S. Le Pogam7, I. Nájera7, P. Smith7, N. Shulman5, J. Tran5
1Centre CAP; 2Saint Eloi Hospital, Montpellier, France; 3Auckland Clinical Studies,
Auckland, New Zealand; 4Medical University of Warsaw, Warszawa, Poland; 5Roche, South San Francisco, CA, USA; 6Roche, Welwyn, UK; 7Roche, Nutley, NJ, USA
![croi1.gif](../images/040111/040111-6/croi1.gif)
![croi2.gif](../images/040111/040111-6/croi2.gif)
![croi3.gif](../images/040111/040111-6/croi3.gif)
![croi4.gif](../images/040111/040111-6/croi4.gif)
![croi5.gif](../images/040111/040111-6/croi5.gif)
![croi6.gif](../images/040111/040111-6/croi6.gif)
![croi7.gif](../images/040111/040111-6/croi7.gif)
![croi8.gif](../images/040111/040111-6/croi8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|